Tag: CatalYm

March 1, 2022 Off

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

– CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization MUNICH–(BUSINESS WIRE)–CatalYm today…

January 28, 2021 Off

CatalYm begins clinical development of CTL-002 to treat certain oncology patients

By Dino Mustafić

CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry into the tumor microenvironment.